COVID-19 Admissions: trying to define the real impact of infection in hospitalized patients

Introduction and objective: Several studies have suggested that the hospitalization rate for COVID-19 in children and adolescents may reflect the prevalence of the infection rather than the severity of the disease. The aim of this study was to describe the clinical features of hospitalised paediatric patients with SARS-CoV-2 infection in order to understand if the infection was the reason for admission. Methods: Retrospective cohort study including patients aged 0 to 18 years with SARS-CoV-2 infection or multisystem inflammatory syndrome in children (MIS -C) admitted to a tertiary care children's hospital in Spain between 01/01/2020 and 12/31/2021. Results: 228 patients were included, corresponding to 150 cases of COVID-related admission (SARS-CoV-2 infection as main cause of hospitalization) and 78 of non-COVID-related admission (SARS-CoV-2 infection unrelated to the hospitalization). In the group of COVID-related admissions, 58 patients had comorbidities. Forty-nine patients had acute respiratory disease (pneumonia, bronchospasm or bronchiolitis). Multisystem inflammatory syndrome in children was diagnosed in 27 and was significantly more frequent in the first year of the pandemic (wild type virus). Eighty percent of patients with acute respiratory disease needed respiratory support, mostly low -flow oxygen therapy. The severity of the disease was similar in all virus variants. Two patients (both with severe comorbidities) died from COVID-related conditions. Conclusions: In our study, one third of the patients were admitted with SARS-CoV-2 infection but not because of it . Acute respiratory disease was less frequent and had a better prognosis compared to the adult population, while MIS -C was a major cause of morbidity and hospitalization. The fatality rate was extremely low. (c) 2024 Asociaci & oacute;n Espa & ntilde;ola de Pediatr & iacute;a. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).